
Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.
In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs. Here, we will give a short insight into our published results.
Enrolment
Eingeschlossene Patienten: 20.147 (Stand 1. Januar 2021) | |
---|---|
Amgevita® (Adalimumab) | 103 |
Benepali® (Etanercept) | 760 |
Cimzia® (Certolizumab) | 943 |
Enbrel® (Etanercept) | 2865 |
Erelzi® (Etanercept) | 320 |
Flixabi® (Infliximab) | 8 |
Hulio® (Adalimumab) | 62 |
Humira® (Adalimumab) | 2903 |
Hyrimoz® (Adalimumab) | 79 |
Idacio® (Adalimumab) | 16 |
Imraldi® (Adalimumab) | 101 |
Inflectra™ (Infliximab) | 16 |
Kevzara® (Sarilumab) | 146 |
Kineret® (Anakinra) | 89 |
MabThera® (Rituximab) | 1458 |
Nepexto® (Etanercept) | 6 |
Olumiant® (Baricitinib) | 423 |
Orencia® (Abatacept) | 857 |
Remicade® (Infliximab) | 762 |
Remsima® (Infliximab) | 11 |
Rinvoq® (Upadacitinib) | 111 |
Rixathon® (Rituximab) | 14 |
RoActemra® (Tocilizumab) | 1330 |
Simponi® (Golimumab) | 446 |
Xeljanz® (Tofacitinib) | 331 |
Zessly® (Infliximab) | 2 |
Kontrollen | 5985 |
Update: August 1st, 2018; enrolled patients: 17,522
Benepali® (Etanercept) | 447 |
Cimzia® (Certolizumab) | 841 |
Enbrel® (Etanercept) | 2859 |
Erelzi® (Etanercept) | 65 |
Flixabi® (Infliximab) | 1 |
Humira® (Adalimumab) | 2883 |
Inflectra® (Infliximab) | 16 |
Kevzara® (Sarilumab) | 20 |
Kineret® (Anakinra) | 89 |
MabThera® (Rituximab) | 1459 |
Olumiant® (Baricitinib) | 167 |
Orencia® (Abatacept) | 718 |
Remicade® (Infliximab) | 762 |
Remsima® (Infliximab) | 9 |
RoActemra® (Tocilizumab) | 1260 |
Simponi® (Golimumab) | 428 |
Xeljanz® (Tofacitinib) | 106 |
Control Group | 5392 |